|
|
Phase II Study of AZD2171 in Patients With Recurrent Glioblastoma Multiforme
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outcomes Outline Trial Contact Information Registry Information
Alternate Title
AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
MGH-05-254 NCI-7105, 7105, NCT00305656
|
|
|
Objectives Primary - Determine the proportion of patients with recurrent glioblastoma multiforme (GM) who are alive and progression free 6 months after starting AZD2171 therapy.
Secondary - Assess the biological effect of AZD2171 by using the following MRI techniques: dynamic contrast-enhanced imaging; arterial spin-labeling imaging; perfusion-weighted imaging; and diffusion- tensor imaging at serial time points.
- Measure circulating endothelial and progenitor cells and plasma levels of tumstatin, (vascular endothelial growth factor (VEGF)-A and –D, sVEGF receptors, P1GF, platelet-derived growth factor (PDGF)-AA, PDGF-AB, PDGF-BB, Ang1, thrombospondin-1, and interleukin-8 as markers for response to antiangiogenic therapy in recurrent GM.
- Correlate treatment outcomes with pre-AZD2171 tumor specimens with respect to microvascular density, basement membrane and pericyte coverage, and angiopoietin-1 and -2 expression to determine whether these immunohistochemical analyses can be predictive of the response to AZD2171.
- Measure polymorphisms of kdr/flk-1 gene and genetic analysis of HIF1-alpha, TP53, and endothelial nitric oxide synthase genes in the archival tumor specimens.
- Determine the overall survival of patients with recurrent GM treated with AZD2171.
- Determine the radiographic response rate in patients with recurrent GM treated with AZD2171.
- Determine the safety of AZD2171 in this patient population.
Entry Criteria Disease Characteristics:
- Histologically confirmed glioblastoma multiforme
- Measurable contrast-enhancing tumor ≥ 1 cm in longest diameter by baseline MRI or CT scan
- Patient must have been on no steroids OR a stable dose of steroids for ≥ 5 days prior to baseline MRI or CT scan
- Patients who are on steroids must be maintained on a stable corticosteroid regimen from baseline scan until the start of study treatment
- No intratumoral or peritumoral hemorrhage by MRI
Prior/Concurrent Therapy:
- See Disease Characteristics
- Recovered from toxicity of prior therapy
- At least 3 months since prior radiation therapy, including cranial radiation therapy
- At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas)
- At least 3 weeks since prior molecularly-targeted agents
- At least 4 weeks since prior major surgery
- No more than 2 prior chemotherapy regimens or antineoplastic drugs
- More than 30 days since prior participation in an investigational trial
- At least 2 weeks since prior enzyme-inducing antiepileptic drugs (EIAEDs)
- No concurrent EIAEDs
- Concurrent non-EIAEDs allowed
- No concurrent combination antiretroviral therapy for HIV-positive patients
- No other concurrent investigational agents
- No concurrent vascular endothelial growth factor inhibitors
- Prior thalidomide or lenolidomide allowed
- No concurrent anticoagulants (e.g., warfarin) or antiplatelet agents including aspirin
- No other concurrent anticancer agents or therapies
- No concurrent grapefruit juice
Patient Characteristics:
- Karnofsky performance status ≥ 60%
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No other concurrent malignancy within the past 5 years except curatively treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast
- Mini-mental status examination score ≥ 15
- WBC ≥ 3,000/mm3
- Absolute neutrophil count ≥ 1,500/mm3
- Platelet count ≥ 100,000/mm3
- Hemoglobin ≥ 8 g/dL
- Bilirubin normal
- AST/ALT ≤ 2.5 times upper limit of normal
- Creatinine normal OR creatinine clearance ≥ 60 mL/min
- No history of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD2171
- Mean QTc ≤ 470 msec (with Bazett's correction) on screening electrocardiogram
- No history of familial long QT syndrome
- No greater than +1 proteinuria on 2 consecutive dipsticks taken ≥ 1 week apart unless first urinalysis shows no protein
- No uncontrolled intercurrent illness, including, but not limited to, any of the following:
- Hypertension
- Ongoing or active infection
- Symptomatic congestive heart failure
- Unstable angina pectoris
- Cardiac arrhythmia
- Psychiatric illness/social situations that would limit compliance with study requirements
- No known coagulopathy that increases the risk of bleeding
- No history of clinically significant hemorrhages
Expected Enrollment 31A total of 31 patients will be accrued for this study. Outcomes Primary Outcome(s)Progression-free survival at 6 months
Secondary Outcome(s)Response Overall survival Toxicity
Outline This is a multicenter study. Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed periodically for up to 12 months.
Trial Contact Information
Trial Lead Organizations Massachusetts General Hospital | | | Tracy Batchelor, MD, MPH, Protocol chair | | Ph: 617-643-1938; 877-726-5130 |
| |
Registry Information | | Official Title | | A Phase II Study of AZD2171 in Recurrent Glioblastoma | | Trial Start Date | | 2005-12-21 | | Registered in ClinicalTrials.gov | | NCT00305656 | | Date Submitted to PDQ | | 2005-11-17 | | Information Last Verified | | 2007-01-04 | | NCI Grant/Contract Number | | CA117079 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|